Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.49 |
| ▸ | LSS | P48449 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1449252 | 1.00 | L3MBTL3 (0.49) | L3MBTL3LSSL3MBTL1HRH3POLB | |
| SCHEMBL24185235 | 0.82 | L3MBTL3 (0.71) | L3MBTL3L3MBTL1HRH3POLBKMT2A | |
| SCHEMBL2887400 | 0.82 | L3MBTL3 (0.71) | L3MBTL3L3MBTL1HRH3POLBKMT2A | |
| SCHEMBL24185230 | 0.82 | L3MBTL3 (0.71) | L3MBTL3L3MBTL1HRH3POLBKMT2A | |
| SCHEMBL1448699 | 0.81 | MCHR1 (0.53) | L3MBTL3L3MBTL1HRH3POLBKMT2A | |
| SCHEMBL1448332 | 0.78 | L3MBTL3 (0.52) | L3MBTL3L3MBTL1HRH3POLBKMT2A | |
| SCHEMBL8150280 | 0.77 | KMT2A (0.45) | L3MBTL1KMT2A | |
| SCHEMBL26773746 | 0.76 | L3MBTL3 (0.84) | L3MBTL3L3MBTL1HRH3POLBKMT2A | |
| SCHEMBL1448975 | 0.75 | L3MBTL3 (0.52) | L3MBTL3LSSL3MBTL1HRH3HPGD | |
| SCHEMBL4862362 | 0.75 | L3MBTL3 (0.52) | L3MBTL3LSSL3MBTL1HRH3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301928-A1 | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| EP-1912974-A1 | IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015064-A1 | IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | CCNI, MKI67, TYMP | L3MBTL3 3141/4885LSS 1740/4885L3MBTL1 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.